1
|
Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z, Nakashima T, Morisawa T, Hashiramoto A, Shiozawa K, Ishikawa H, Kurosaka M, Shiozawa S. Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003; 22:6839-44. [PMID: 14534529 DOI: 10.1038/sj.onc.1206903] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Wee1 kinase downregulates the M-phase promoting factor, a complex of cdc2 and cyclin B kinase, that controls mitotic cell division. We isolated human wee1 kinase gene promoter and found that it contained one AP-1-binding motif in its promoter region (5'-CGAGTCA-3'; -823/-817), through which wee1 kinase gene was directly transactivated by c-Fos/AP-1. In rheumatoid synovial cells, wee1 kinase was increased in conjunction with the increase of c-Fos/AP-1 and the substrate of wee1, cdc2, was phosphorylated. The amount of wee1 and c-Fos and the phosphorylation of cdc2 were decreased after treatment of the cells with an inhibitor of AP-1, curcumin. A significant proportion of cultured synovial cells of the patients with rheumatoid arthritis, but not those of osteoarthritis, shifted to a tetraploid (4C) state upon long-term culture. Thus, human wee1 kinase gene is directly transactivated by and increased in association with c-Fos/AP-1, and rheumatoid synovial cells overexpressing these genes go into aberrant mitosis.
Collapse
Affiliation(s)
- Hiroki Kawasaki
- Department of Rheumatology, Kobe University FHS School of Medicine, Kobe 654-0142, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Hikasa M, Yamamoto E, Kawasaki H, Komai K, Shiozawa K, Hashiramoto A, Miura Y, Shiozawa S. p21waf1/cip1 is down-regulated in conjunction with up-regulation of c-Fos in the lymphocytes of rheumatoid arthritis patients. Biochem Biophys Res Commun 2003; 304:143-7. [PMID: 12705898 DOI: 10.1016/s0006-291x(03)00574-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Features characteristic to rheumatoid arthritis (RA) including synovial overgrowth and joint destruction are experimentally produced by augmenting c-fos gene expression. We show that cyclin dependent kinase inhibitor p21waf1/cip1, that inhibits cell proliferation, is down-regulated in conjunction with up-regulation of c-fos in the lymphocytes of patients with RA. As to the mechanism of down-regulation of p21waf1/cip1 gene expression, transfection studies in U937 cells showed that c-fos down-regulated phosphorylation and dimerization of signal transducers and activators of transcription (STAT) 1, thereby inhibiting interferon -induced transactivation of p21waf1/cip1. Phosphorylation of STAT1 was indeed decreased in the lymphocytes of patients with RA. Thus, under overexpression of c-fos gene, c-Fos inactivates STAT1 to down-regulate p21waf1/cip1 gene expression in the lymphocytes of patients with RA, and in this way may enhance proliferation of lymphocytes.
Collapse
Affiliation(s)
- Mari Hikasa
- Department of Rheumatology, Faculty of Health Science, Kobe University School of Medicine, 654-0142, Kobe, Japan
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
The novel protein kinase C (PKC) isoform, PKC theta, is selectively expressed in T lymphocytes and is a sine qua non for T cell antigen receptor (TCR)-triggered activation of mature T cells. Productive engagement of T cells by antigen-presenting cells (APCs) results in recruitment of PKC theta to the T cell-APC contact area--the immunological synapse--where it interacts with several signaling molecules to induce activation signals essential for productive T cell activation and IL-2 production. The transcription factors NF-kappa B and AP-1 are the primary physiological targets of PKC theta, and efficient activation of these transcription factors by PKC theta requires integration of TCR and CD28 costimulatory signals. PKC theta cooperates with the protein Ser/Thr phosphatase, calcineurin, in transducing signals leading to activation of JNK, NFAT, and the IL-2 gene. PKC theta also promotes T cell cycle progression and regulates programmed T cell death. The exact mode of regulation and immediate downstream substrates of PKC theta are still largely unknown. Identification of these molecules and determination of their mode of operation with respect to the function of PKC theta will provide essential information on the mechanism of T cell activation. The selective expression of PKC theta in T cells and its essential role in mature T cell activation establish it as an attractive drug target for immunosuppression in transplantation and autoimmune diseases.
Collapse
Affiliation(s)
- Noah Isakov
- Department of Microbiology and Immunology, Faculty of Health Sciences, and the Cancer Research Center, Ben Gurion University of the Negev, Beer Sheva 84105, Israel.
| | | |
Collapse
|
4
|
Frauwirth KA, Alegre ML, Thompson CB. CTLA-4 is not required for induction of CD8(+) T cell anergy in vivo. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:4936-41. [PMID: 11673499 DOI: 10.4049/jimmunol.167.9.4936] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Recent studies of T cell anergy induction have produced conflicting conclusions as to the role of the negative regulatory receptor, CTLA-4. Several in vivo models of tolerance have implicated the interaction of CTLA-4 and its ligands, B7.1 and B7.2, as an essential step in induction of anergy, while results from a number of other systems have indicated that signals from the TCR/CD3 complex alone are sufficient to induce T cell unresponsiveness. One explanation for this disparity is that the requirements for anergy induction depend closely on the details of the system: in vivo vs in vitro, route of stimulus administration, naive vs memory cells, CD4(+) vs CD8(+) cells, etc. To test this possibility, we established an in vivo anergy model using mice transgenic for the 2C TCR on a recombination-activating gene-2-deficient background, that either express or lack the CTLA-4 molecule. This system provides us with a very homogeneous pool of naive Ag-specific CD8(+) T cells, allowing us to control some of the conditions mentioned above. We found that T cells from CTLA-4-deficient mice were anergized by injections of soluble antigenic peptide as efficiently as were CTLA-4-expressing cells. These results indicate that CTLA-4 is not universally required for in vivo T cell anergy induction and may point to distinctions between regulation of peripheral tolerance in CD4(+) and CD8(+) T cells.
Collapse
Affiliation(s)
- K A Frauwirth
- Abramson Family Cancer Research Institute and Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | | |
Collapse
|
5
|
Kawasaki H, Komai K, Ouyang Z, Murata M, Hikasa M, Ohgiri M, Shiozawa S. c-Fos/activator protein-1 transactivates wee1 kinase at G(1)/S to inhibit premature mitosis in antigen-specific Th1 cells. EMBO J 2001; 20:4618-27. [PMID: 11500387 PMCID: PMC125577 DOI: 10.1093/emboj/20.16.4618] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
M-phase promoting factor is a complex of cdc2 and cyclin B that is regulated positively by cdc25 phosphatase and negatively by wee1 kinase. We isolated the wee1 gene promoter and found that it contains one AP-1 binding motif and is directly activated by the immediate early gene product c-Fos at cellular G(1)/S phase. In antigen-specific Th1 cells stimulated by antigen, transactivation of the c-fos and wee1 kinase genes occurred sequentially at G(1)/S, and the substrate of wee1 kinase, cdc2-Tyr15, was subsequently phosphorylated at late G(1)/S. Under prolonged expression of the c-fos gene, however, the amount of wee1 kinase was increased and its target cdc2 molecule was constitutively phosphorylated on its tyrosine residue, where Th1 cells went into aberrant mitosis. Thus, an immediate early gene product, c-Fos/AP-1, directly transactivates the wee1 kinase gene at G(1)/S. The transient increase in c-fos and wee1 kinase genes is likely to be responsible for preventing premature mitosis while the cells remain in the G(1)/S phase of the cell cycle.
Collapse
Affiliation(s)
- Hiroki Kawasaki
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Koichiro Komai
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Zhufeng Ouyang
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Miki Murata
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Mari Hikasa
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Mami Ohgiri
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| | - Shunichi Shiozawa
- Division of Clinical Immunology, Faculty of Health Science, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142 and Department of Rheumatology and Medicine, Kobe University Hospital, 7-5-2 Kusunoki-cho, chuou-ku, Kobe 654-0017, Japan Corresponding author e-mail:
| |
Collapse
|